display Latest news from Spark Therapeutics on News en-us Copyright 2024 News 115 31 / /images/newswise-logo-rss.gif /articles/spark-therapeutics-and-pfizer-announce-publication-in-the-new-england-journal-of-medicine-of-interim-data-from-phase-1-2-clinical-trial-of-investigational-gene-therapy-for-hemophilia-b/?sc=rsin /articles/spark-therapeutics-and-pfizer-announce-publication-in-the-new-england-journal-of-medicine-of-interim-data-from-phase-1-2-clinical-trial-of-investigational-gene-therapy-for-hemophilia-b/?sc=rsin Wed, 06 Dec 2017 17:00:00 EST Spark Therapeutics (NASDAQ: ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer Inc. (NYSE:PFE), today announced that The New England Journal of Medicine has published interim data as of July 25, 2017, from the Phase 1/2 clinical trial of SPK-9001, an investigational gene therapy for hemophilia B. Spark Therapeutics /articles/spark-therapeutics-announces-publication-in-the-lancet-of-pivotal-phase-3-clinical-trial-data-for-investigational-voretigene-neparvovec/?sc=rsin /articles/spark-therapeutics-announces-publication-in-the-lancet-of-pivotal-phase-3-clinical-trial-data-for-investigational-voretigene-neparvovec/?sc=rsin Thu, 13 Jul 2017 18:30:00 EST Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 data at year one for investigational voretigene neparvovec an investigational, potential one-time gene therapy candidate for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD). Spark Therapeutics